Frizzled-2

Frizzled-2 Molekülinformation

Englischer Name	Frizzled-2	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	Frizzled Class Receptor 2，Frizzled 2， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 2，FzE2，Fz-2
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Englischer Name	Frizzled-2
Target-Alias	Frizzled Class Receptor 2，Frizzled 2， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 2，FzE2，Fz-2
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Frizzled-2 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
Fc Tag (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
FZ2-H5251	Human	HEK293	Human Frizzled-2 / FZD2 Protein, Fc Tag				In den Warenkorb legen
FZ2-H5255	Human	HEK293	Human Frizzled-2 / FZD2 (24-190) Protein, Fc Tag				In den Warenkorb legen

Gesamtmenge2

Produktanfrage

Frizzled-2 Molekülhintergrund

Frizzled-2 (FZD2) is also known as FzE2, which belongs to the G-protein coupled receptor Fz/Smo family. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. FZD2 contains one FZ (frizzled) domain. FZD2 may be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. The Lys-Thr-X-X-X-Trp motif of FZD2 interacts with the PDZ doman of Dvl (Disheveled) family members and is involved in the activation of the Wnt/beta-catenin signaling pathway.

Frizzled-2 Molekülalias

FZD2,Frizzled-2,Fz-2,hFz2,FzE2

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Vantictumab	OMP-18R5; anti-Fzd7	Phase 1 Clinical	Bayer AG, Oncomed Pharmaceuticals Inc	Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Osteopetrosis; Pancreatic Neoplasms; Solid tumours	Details